Do you want to read an article? Please log in or register.
Incidence and predictors of recurrent venous thromboembolism after isolated distal deep vein thrombosis: a post-hoc analysis of the RIDTS trial
Non-Malignant Blood Disorders
Related content
Further Publications
Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial
Lancet Haematol
Mahé I, Chapelle C, Girard P, Carrier M, Palomares LJ, Samama CM, Helfer H, Gerotziafas G, Laporte S, Vicaut E, Mismetti P, API-CAT Study Group, API-CAT Investigators
doi: 10.1016/S2352-3026(25)00291-1
Gynecologic Cancer
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial
★ 3
Recommended and commented by
Dr Andreas Müller, Faculty Member
★ 1
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
Lancet Oncol
Post CCB, de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Leary A, Ottevanger PB, McCormack M, Khaw P, D'Amico R, Fyles A, Chargari C, Kitchener HC, Do V, Lissoni A, Provencher D, Genestie C, Nijman HW, Whitmarsh K, Jürgenliemk-Schulz IM, Feeney A, Lutgens LCHW, Bouma J, Leon-Castillo A, Nout RA, Putter H, Bosse T, Creutzberg CL
doi: 10.1016/S1470-2045(25)00379-1
Non-Malignant Blood Disorders
Molecular Determinants of Thrombosis Recurrence Risk Across Venous Thromboembolism Subtypes
Blood
Munsch G, Thibord F, Bezerra OC, Brody JA, van Hylckama Vlieg A, Gourhant L, Chen MH, Samaria F, Germain M, Caro I, Suchon P, Olaso R, Wiggins KL, Saut N, Besse C, Goumidi L, Bacq D, Harrington LB, Boland A, Emmerich J, Smadja DM, Lemarie CA, Danckwardt S, Debette S, Deleuze JF, Jacqmin-Gadda H, Rodger MA, Gagnon F, Rosendaal FR, Johnson AD, Smith NL, Couturaud F, Morange PE, Tregouet DA
doi: 10.1182/blood.2024027879
Gastrointestinal Cancer
Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial
JAMA Oncol
Zhang GQ, Meyerhardt JA, Shi Q, Twombly T, Pederson L, Ma C, Väyrynen JP, Zhao M, Takashima Y, Shergill A, Kumar P, Couture F, Kuebler P, Krishnamurthi S, Tan B, O'Reilly EM, Giannakis M, Ogino S, Jurdi A, Sharma S, Aleshin A, Shields AF, Nowak JA
doi: 10.1001/jamaoncol.2025.5144
RECOMMENDED
Breast Cancer
Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial
★ 1
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
Lancet Oncol
Yuan J, Bi XW, Hua X, Huang H, Cai L, Zhao L, Chen QJ, Chen XX, Wang XL, Lin Y, Zhang AQ, Zhong YY, Xu F, Huang JJ, An X, Shi YX, Wang X, Wang SS, Xue C, Yuan ZY
doi: 10.1016/S1470-2045(25)00545-5
Gastrointestinal Cancer
Durvalumab Plus Chemotherapy for Advanced Biliary Tract Cancer: A Post Hoc Analysis of the TOPAZ-1 Randomized Clinical Trial
JAMA Oncol
Oh DY, He AR, Qin S, Chen LT, Okusaka T, Griffin R, Wang J, Xynos I, Vogel A, Valle JW
doi: 10.1001/jamaoncol.2026.2204
Genitourinary Cancer
Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by age
Eur J Cancer
Shore ND, De Giorgi U, Kalac M, Tang Y, Croitoru R, Rosales M, Huynh MJ, de Jong IJ, Evans CP, Carcano FM, Freedland SJ
doi: 10.1016/j.ejca.2025.116110
RECOMMENDED
Further Publications
Reduced-Dose Versus Full-Dose Direct Oral Anticoagulants for Extended Secondary Venous Thromboembolism Prophylaxis in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Trials
★ 2
Recommended by
Dr Andreas Müller, Faculty Member
Am J Hematol
Mahmoud A, Eltaher B, Shah P, Vengilote R, Mostafa M, Afzal A, Sanfilippo KM
doi: 10.1002/ajh.70090
Lung, Respiratory and Thoracic Cancer
Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial
Lancet Oncol
Brunetti L, Santo V, Pinato DJ, Citarella F, Orlando S, Acker F, Colella V, Ricciuti B, Naidoo J, Nassar A, Wakelee HA, Takada K, Naqash AR, Garassino MC, Greco C, Ramella S, Pantano F, Tonini G, Vincenzi B, Arlunno B, Remon J, Parisi C, Planchard D, Besse B, Desilets A, Routy B, Elkrief A, Barlesi F, Derosa L, Cortellini A
doi: 10.1016/S1470-2045(26)00191-9